Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Early trial results have been promising, fueling significant interest among both patients and healthcare providers
Patients on semaglutide who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group
A Look at GLP-1 Results According to researchers at Shenandoah University, the medication produced clinically significant weight loss during trials conducted as part of the Semaglutide Treatment Effect in People with Obesity (STEP) program
Women with diabetes have a higher risk of recurrent vaginal yeast infections
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for several indications: type 2 diabetes mellitus, chronic weight management, and more recently, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity
US$ 20.27
US$ 20.21
US$ 29.41
US$ 21.18
US$ 24.47
US$ 21.26
US$ 27.03
